NMOSD as defined by the 2015 international consensus diagnostic criteria (AQP4+ only)
With NMOSD treatment (treatment must be unchanged since 6 months before enrollment, and 1 month for analgesics, antidepressants, neuroleptics)
EDSS =\< 7
With no evidence of relapse in the past 3 months before enrollment
Who have read the information sheet and signed the informed consent form
Able to use a smartphone
Owns a personal smartphone which version is above 13 for IOS and 8 for Android included
Able to read language in which the mobile application is available and able to understand pictograms
You may not be if
Evidence of neurologic, rheumatologic or psychiatric disorder other than NMOSD, including but not limited to major head trauma, seizures or systemic medical diseases that are likely to affect cognitive, upper limb or lower limb functioning
Pregnant and nursing women
Person under guardianship or curatorship
Bedridden patients or patients with a daily activity of less than 2 hours per day
Current drugs or/and alcohol abuse that could influence performance on the tests (clinician's judgment)
Subject has participated in another clinical study within the previous 30 days of screening or is currently participating in another study that, in the opinion of the Investigator, might interfere with the participant's full participation in the study or confound the assessment of the participant or outcome of the study.
Clareo Health | Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
